Financial Performance - The company's operating revenue for 2023 was CNY 2,340,945,518, a decrease of 2% compared to CNY 2,388,617,678 in 2022[21]. - Net profit attributable to shareholders increased by 17.41% to CNY 57,000,674.55 from CNY 48,548,121.74 in the previous year[23]. - Cash flow from operating activities decreased by 32.47% to CNY 215,590,355.95, down from CNY 319,232,403.36 in 2022[23]. - Basic and diluted earnings per share rose by 22.22% to CNY 0.11, compared to CNY 0.09 in 2022[22]. - The weighted average return on equity increased by 0.35 percentage points to 2.42% from 2.07% in the previous year[22]. - Total assets decreased by 3.15% to CNY 3,279,335,678.82 from CNY 3,386,135,812.03 in 2022[21]. - The net asset attributable to shareholders increased slightly by 0.36% to CNY 2,335,387,196.13 from CNY 2,327,112,527.12 in 2022[21]. - The net profit after deducting non-recurring gains and losses increased by 0.84% to CNY 49,103,973.11[23]. - The total profit for 2023 was 83.41 million yuan, representing a year-on-year increase of 31.92%[32]. - The company reported a significant decline in cash flow due to reduced sales revenue and slower cash collection[23]. Dividend Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares, totaling 53,407,162.8 RMB based on a total share capital of 534,071,628 shares as of December 31, 2023[5]. - The company distributed a cash dividend of 1 RMB per 10 shares, totaling 53,407,162.80 RMB, which represents 93.70% of the net profit attributable to ordinary shareholders in the consolidated financial statements[193]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[4]. - There are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has not faced any issues with more than half of the directors being unable to ensure the authenticity and completeness of the annual report[9]. - The company has confirmed that the financial report is true, accurate, and complete as stated by the responsible persons[5]. - The company has not disclosed any significant changes in its registered address or office location[16]. - The company has conducted self-inspections regarding fund occupation and illegal guarantees, confirming compliance with regulations and no violations found[159]. - The internal control audit report received a standard unqualified opinion[197]. - There were no significant deficiencies in internal control during the reporting period[197]. Risk Management - The company has detailed potential risks in the section discussing future development in the annual report[9]. - The company emphasizes the importance of investor awareness regarding the risks associated with forward-looking statements in the annual report[6]. - The company has established mechanisms for environmental protection[200]. - The company recognizes quality control risks stemming from complex production processes and has established measures to enhance quality management capabilities, including ongoing training and process monitoring[152]. - The company will enhance its internal control management system to improve operational efficiency and risk management capabilities[141]. Research and Development - Continuous investment in R&D led to multiple technological innovations and quality standard improvements, with some results achieving domestic leading levels[40]. - The company is actively working on enhancing the quality standards of traditional Chinese medicine and ethnic medicine, aiming to include more varieties in the Chinese Pharmacopoeia[41]. - The company has made progress in the technical enhancement and quality standard improvement of potential products, opening new sales growth points[42]. - The company has increased its R&D investment in traditional Chinese medicine, achieving multiple technological innovations and quality standard improvements, with some results already applied in production and pending national patent applications[97]. - The company’s R&D projects include the development of new indications for existing drugs, with ongoing basic research in various therapeutic areas[110]. - The company has a research and development team of 203 personnel, with over 56% holding bachelor's degrees or higher, focusing on various pharmaceutical disciplines[107]. - The company applied for 5 invention patents and 9 utility model patents in 2023, reinforcing its commitment to intellectual property protection[70]. - The total R&D expenditure for the company was RMB 90,940.92 million, which is 38.85% of its revenue, a decrease of 3.13 percentage points year-on-year[120]. Market and Industry Trends - The pharmaceutical industry in China experienced a decline in overall growth, with the industrial added value of large-scale pharmaceutical enterprises approximately 1.3 trillion yuan, a year-on-year decrease of 5.2%[51]. - The revenue of pharmaceutical industrial enterprises reached 2.95525 trillion yuan, down 4% year-on-year, while profits fell to 412.72 billion yuan, a decrease of 16.2%[51]. - Different sub-industries showed varied performance, with traditional Chinese medicine (TCM) and Chinese patent medicines maintaining positive growth rates of 14.6% and 6.5% respectively, while chemical raw materials and biological products saw significant declines[52]. - The overall pharmaceutical market in China is projected to grow at a compound annual growth rate (CAGR) of 9.6% from 2020 to 2025[130]. - The company anticipates a decline in revenue and profit due to ongoing policy changes in the pharmaceutical industry, with a focus on adapting to these changes to maintain profitability[143]. Corporate Governance - The company has a governance structure that complies with the latest regulations, ensuring effective operation and protection of shareholder rights, particularly for minority shareholders[156]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirement for independent oversight[157]. - The company has established transparent performance evaluation and incentive mechanisms for senior management to promote long-term stability and development[158]. - The company has maintained a stable governance structure with independent directors and a supervisory board that operates independently[160]. - The company has a structured approach to evaluating and compensating its directors and senior management[175]. Environmental Responsibility - The company has implemented a strict environmental responsibility system, including an "environmental veto" policy and increased investment in environmental protection measures[150]. - The company invested 2.6165 million yuan in environmental protection during the reporting period[200]. - There were no administrative penalties related to environmental issues during the reporting period[200]. - The company adheres to various environmental discharge standards for air and water pollutants[200]. Strategic Initiatives - The company implemented a strategy of "focus, optimization, and integration" to enhance operational efficiency and adapt to industry changes[36]. - The company aims to enhance its brand value and market influence, having received multiple awards in 2023, including "Top 100 Chinese Traditional Medicine Enterprises" and "Outstanding Brand Enterprise in Chinese Medicine" for its loquat cough series products[46][47]. - The company plans to focus on innovation and quality, aiming to enhance brand value and market influence while expanding into various business areas including manufacturing and e-commerce[133]. - The company will enhance R&D and innovation capabilities, focusing on core products in oncology and cardiovascular areas, utilizing both "internal growth and external expansion" strategies for new vitality[134]. - The company aims to develop a series of single products with over 100 million in sales, focusing on traditional Chinese medicine as a new profit growth point[140].

证券代码：A 股 600613 股票简称：A 股 神奇制药 编号：2024-016 B 股 900904 B 股 神奇 B 股 上海神奇制药投资管理股份有限公司 2024 年一季度主要运营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、运营数据 1．主营业务分行业情况 单位：元 2．主营业务分类情况 单位：元 | | | | | 营业收 | 营业成本 | 毛利率 | | --- | --- | --- | --- | --- | --- | --- | | | | | 毛利率 | 入比上 | 比上年同 | 比上年 | | 分产品 | 营业收入 | 营业成本 | | 年同期 | | | | | | | （%） | 增减 | 期增减 | 同期增 | | | | | | | （%） | 减（%） | | | | | | （%） | | | | 抗肿瘤药 | 135,337,641.87 | 13,371,014.18 | 90.12 | -22.99 | -3.82 | -1.97 | | 系列 | | | | ...

| 证券代码：A | 股 600613 | 股票简称：A | 股 神奇制药 | | 编号：2024-008 | | --- | --- | --- | --- | --- | --- | | B | 股 900904 | B | 股 神奇 B | 股 | | 上海神奇制药投资管理股份有限公司 关于参加 2024 年上海辖区上市公司年报集体业绩说 明会的公告 届时公司的董事总经理冯斌先生、独立董事段竞晖先生、财务总监陈之勉先 生和董事会秘书吴克兢先生将通过网络在线交流形式与投资者就公司治理、发展 战略、经营状况、融资计划、股权激励和可持续发展等投资者关注的问题进行沟 通。 欢迎广大投资者积极参与。 特此公告。 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●会议召开时间： 2024 年 5 月 10 日（周五）15:00 至 17:00 ●会议召开方式：上证路演中心网络互动 ● 会议召开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.s ...

| 证券代码：A | 股 600613 | 证券简称：A | 股 神奇制药 | 公告编号：2024-007 | | --- | --- | --- | --- | --- | | B | 股 900904 | B | 股 神奇 B 股 | | 上海神奇制药投资管理股份有限公司 关于控股股东协议转让部分股份完成过户登记的公告 三、过户登记完成后股东持股情况 1 本次权益变动前，神奇控股持有公司股份数量为 120,661,620 股，占公司总 股本的 22.59%。本次权益变动后，神奇控股持股数量为 90,661,620 股，占公 司总股本的 16.98%。 本次权益变动前，知几 2 号不持有公司股份。本次权益变动后，受让方将持 有公司 30,000,000 股股份，占公司总股本的 5.62%。本次协议转让不会触发受 让方的要约收购义务。 本次权益变动前后，股东权益变动情况如下： 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带责任。 上海神奇制药投资管理股份有限公司（以下简称"公司"）于 2024 年 4 月 18 日 ...

上海神奇制药投资管理股份有限公司 简式权益变动报告书 （修订版） 上市公司名称：上海神奇制药投资管理股份有限公司 股票上市地点：上海证券交易所 股票简称：神奇制药 股票代码：600613 四、本次股份协议转让尚需上海证券交易所进行合规性审核，并在中国证券登记结算有限责任公 司上海分公司办理完成股份过户登记手续。 信息披露义务人：杭州雀石私募基金管理有限公司－雀石知几2号私募证券投资基金 基金备案编号：SADD86 管理人名称：杭州雀石私募基金管理有限公司 股份变动性质：股份增加（协议转让） 签署日期：2024年3月21日 1 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、《上 市公司收购管理办法》（以下简称"《收购管理办法》"）、《公开发行证券的公司信息披露内容与格式准 则第15号——权益变动报告书》及相关的法律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《证券法》、《收购管理办法》的规定，本报告书已全面披露了信息披露义务人在上海 神奇制药投资管理股份有限公司中拥有权益的股份变动情况。 截至本报告书签署之日 ...

证券代码：A 股 600613 证券简称：A 股 神奇制药 公告编号：2024-006 B 股 900904 B 股 神奇 B 股 上海神奇制药投资管理股份有限公司 关于修订控股股东协议转让部分股份暨权益变动相 关公告的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带责任。 上述公告披露了公司控股股东贵州神奇控股（集团）有限公司（以下简称"神 奇控股"）与杭州雀石私募基金管理有限公司－雀石知几 2 号私募证券投资基金 （简称"知几 2 号"或"受让方"）于 2024 年 3 月 21 日签署了《股份转让协议》， 拟通过协议转让方式将其持有的公司 30,000,000 股无限售流通股份（占公司总 股本的 5.62%）以 6.40 元/股的价格转让给受让方，转让价款为人民币 192,000,000 元。 2024 年 3 月 25 日，公司收到神奇控股与知几 2 号函告称，神奇控股与知几 2 号对其双方于 2024 年 3 月 21 日签订的《股份转让协议》进行了修订，并需对 《简式权益变动报告书》中的相关内容进行 ...

上海神奇制药投资管理股份有限公司 简式权益变动报告书 （修订版） 上市公司名称：上海神奇制药投资管理股份有限公司 股票上市地点：上海证券交易所 股票简称：神奇制药 股票代码：600613 信息披露义务人：贵州神奇控股（集团）有限公司 住所/通讯地址：贵州省贵阳市云岩区北京路１号 股份变动性质：股份减少（协议转让） 信息披露义务人之一致行动人：贵州迈吉斯投资管理有限公司 住所:贵州省贵阳市贵阳国家高新技术产业开发区金阳科技产业园标准厂房辅 助用房 B460 室 通讯地址：贵州省贵阳市云岩区北京路１号 信息披露义务人之一致行动人：张之君 住所/通讯地址：贵州省贵阳市云岩区*********** 信息披露义务人之一致行动人：文邦英 住所/通讯地址：贵州省贵阳市云岩区*********** 信息披露义务人之一致行动人：张娅 住所/通讯地址：贵州省贵阳市云岩区*********** 签署日期：2024 年 3 月 21 日 上海神奇制药投资管理股份有限公司 简式权益变动报告书 信息披露义务人声明 2 / 16 一、本报告书系信息披露义务人依据《中华人民共和国证券法》（以下简称 《证券法》）、《上市公司收购管理办法（20 ...

上海神奇制药投资管理股份有限公司 简式权益变动报告书 上市公司名称：上海神奇制药投资管理股份有限公司 股票上市地点：上海证券交易所 股票简称：神奇制药 股票代码：600613 信息披露义务人：贵州神奇控股（集团）有限公司 住所/通讯地址：贵州省贵阳市云岩区北京路１号 股份变动性质：股份减少（协议转让） 信息披露义务人之一致行动人：贵州迈吉斯投资管理有限公司 签署日期：2024 年 3 月 21 日 住所:贵州省贵阳市贵阳国家高新技术产业开发区金阳科技产业园标准厂房辅 助用房 B460 室 通讯地址：贵州省贵阳市云岩区北京路１号 信息披露义务人之一致行动人：张之君 住所/通讯地址：贵州省贵阳市云岩区*********** 信息披露义务人之一致行动人：文邦英 住所/通讯地址：贵州省贵阳市云岩区*********** 信息披露义务人之一致行动人：张娅 住所/通讯地址：贵州省贵阳市云岩区*********** 上海神奇制药投资管理股份有限公司 简式权益变动报告书 信息披露义务人声明 2 / 16 一、本报告书系信息披露义务人依据《中华人民共和国证券法》（以下简称 《证券法》）、《上市公司收购管理办法（2020 年修订 ...

上海神奇制药投资管理股份有限公司 简式权益变动报告书 上市公司名称：上海神奇制药投资管理股份有限公司 信息披露义务人：雀石知几2号私募证券投资基金 基金备案编号：SADD86 管理人名称：杭州雀石投资管理有限公司 股份变动性质：股份增加（协议转让） 签署日期：2024年3月21日 1 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、《上 市公司收购管理办法》（以下简称"《收购管理办法》"）、《公开发行证券的公司信息披露内容与格式准 则第15号——权益变动报告书》及相关的法律、法规和规范性文件编制。 股票上市地点：上海证券交易所 股票简称：神奇制药 股票代码：600613 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《证券法》、《收购管理办法》的规定，本报告书已全面披露了信息披露义务人在上海 神奇制药投资管理股份有限公司中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，上述信息披露义务人没有通过任何其他方式 增加或减少其在上海神奇制药投资管理股份有限公司中拥有权益的股份。 四、本次股份协议转让尚需上海证券交易所进 ...

| 证券代码：A | 股 600613 | 证券简称：A | 股 神奇制药 | 公告编号：2024-005 | | --- | --- | --- | --- | --- | | B | 股 900904 | B | 股 神奇 B 股 | | 上海神奇制药投资管理股份有限公司 关于控股股东协议转让部分股份暨权益变动的提示 性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带责任。 本次权益变动前，受让方不持有公司股份。本次权益变动后，受让方将持有 公司 30,000,000 股股份，占公司总股本的 5.62%。本次协议转让不会触发受让 方的要约收购义务。 本次权益变动前后，股东权益变动情况如下： 重要内容提示： ●本次权益变动为上海神奇制药投资管理股份有限公司（以下简称"公司"） 控股股东贵州神奇控股（集团）有限公司（以下简称"神奇控股"）与雀石知几 2 号私募证券投资基金（简称"知几 2 号"或"受让方"）签署了《股份转让协 议》，拟通过协议转让方式将其持有的公司 30,000,000 股无限售流通股份（占 公 ...